Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lidocaine/prilocaine - Plethora Solutions

Drug Profile

Lidocaine/prilocaine - Plethora Solutions

Alternative Names: Fortacin; Prilocaine Lidocaine Plethora; Prilocaine/lidocaine; PSD-502; SENSTEND; Tempe

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Plethora Solutions
  • Class Acetanilides; Anilides; Class Ib antiarrhythmics; Erectile dysfunction therapies; Local anaesthetics; Non-opioid analgesics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Premature ejaculation
  • Discontinued Pain

Most Recent Events

  • 01 Dec 2021 Plethora Solutions completes a phase II trial for Premature ejaculation in USA (Topical) (NCT03578783)
  • 02 Dec 2020 Wanbang Pharmaceutical receives approval from the National Medical Products Administration (NMPA) to submit the investigational new drug (IND) for Clinical Trial Approval (CTA) for Premature ejaculation in China
  • 17 Nov 2020 Wanbang Pharmaceutical expects to receive investigational new drug (IND) application approval from the National Medical Products Administration (NMPA) for Premature ejaculation by the end of first quarter of 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top